Atlas Lithium Stock Near $4 Before Shareholder Vote: Why ATLX Traders Are Watching Today
Atlas Lithium shares held near $4.15 in early U.S. trading ahead of its annual shareholder meeting
Segg Gains 12% as Jane Street Stake Tangles With Nasdaq Filing
Sports Entertainment Gaming Global Corp. shares rose 12.1% to $1.57 Wednesday after Jane Street disclosed a 5.5% stake. SEGG remains out of Nasdaq compliance due to a late quarterly filing and has
Hall Chadwick Stock Is Stuck Near $10 — The REEcycle Deal Is the Real Test
Hall Chadwick Acquisition Corp. reported $1.65 million in first-quarter net income, driven by $1.84 million in interest from its IPO trust account, with no operating revenue. Shares traded at $10.01, up 1 cent, after the company filed its 10-Q and while its proposed REEcycle merger remains at the letter-of-intent stage.
Traders Eye $850 Million ThomasLloyd Deal as Roman DBDR Stock Stays Quiet
Roman DBDR Acquisition Corp. II closed at $10.52 Wednesday, just below its $10.56 redemption value, with about 115,000 shares traded. The stock’s movement remains tied to its pending merger with ThomasLloyd Climate Solutions, valued at $850 million. Roman reported a Q1 net loss of $235,067 and $242.8 million in its trust account as of March 31. Management cited “substantial doubt” about ongoing operations.
Why Omeros Stock Is Sliding Today Even as Biotech Shares Climb
Omeros shares fell 3.9% to $11.20 in late-morning trading Wednesday, underperforming biotech sector ETFs, which gained. The drop followed the company’s first U.S. launch of YARTEMLEA, which posted $9.9 million in Q1 sales after FDA approval in December. Investors are watching for upcoming reimbursement milestones and a pending European review.
Worksport Stock Gets Patent News — Why WKSP Is Still Fighting for Lift
Worksport Ltd. shares rose about 1% Wednesday after its Terravis Energy unit received a U.S. patent for a heat-pump system designed to reduce frost buildup. The move follows a 15.7% drop in the stock Tuesday. First-quarter net sales climbed 47.9% to $3.31 million, but cash reserves fell to $566,000. Management does not expect revenue from the new technology in 2026.
Honeywell Shares Rise After Quantinuum IPO Sets $12.7 Billion Bar for HON
Honeywell rose 0.9% to $233.86 after its quantum unit Quantinuum set terms for a Nasdaq IPO targeting a $12.7 billion valuation. Quantinuum plans to offer 21.05 million shares at $45–$50 each, expecting net proceeds of about $941.7 million. Honeywell will retain about 49.1% voting power post-offering. Barclays raised its Honeywell price target to $251, maintaining an overweight rating.
Goldman issues warning on CooperCompanies ahead of earnings
CooperCompanies shares rose 0.4% to $62.28 after Goldman Sachs cut its price target to $61 and reiterated a Sell rating. The company’s fiscal Q2 results are due June 4. Cooper posted Q1 revenue of $1.024 billion, up 6%, and set a 2026 adjusted EPS outlook of $4.58 to $4.66. $1.5 billion remains on its 2021 term loan, with a recent U.K. tax ruling noted in its latest 10-Q.
FG Merger II Stock Trades Near Its High After Boxabl Gets Texas Nod, Eyes on June Vote
FG Merger II closed at $10.33 Tuesday, one cent below its 52-week high, after Boxabl secured approval to sell its Casita Studio in Texas. Shareholders are set to vote June 9 on the proposed merger, which would list the combined company as BXBL on Nasdaq if approved.
Casey’s Shares Move Lower Ahead of Results, With Margin Uncertainty in Focus
Casey’s General Stores shares fell 1.9% to $809.41 in early trading Tuesday, even as Wells Fargo raised its price target to $910. The drop came as U.S. indexes climbed, with the S&P 500 up 0.6% and the Nasdaq hitting a record. Wells Fargo warned of a possible fourth-quarter EPS miss due to weaker fuel margins. Casey’s will report fiscal Q4 and full-year results after the bell on June 9.
Goldman issues warning on CooperCompanies ahead of earnings
CooperCompanies shares rose 0.4% to $62.28 after Goldman Sachs cut its price target to $61 and reiterated a Sell rating. The company’s fiscal Q2 results are due June 4. Cooper posted Q1 revenue of $1.024 billion, up 6%, and set a 2026 adjusted EPS outlook of $4.58 to $4.66. $1.5 billion remains on its 2021 term loan, with a recent U.K. tax ruling noted in its latest 10-Q.
FG Merger II Stock Trades Near Its High After Boxabl Gets Texas Nod, Eyes on June Vote
FG Merger II closed at $10.33 Tuesday, one cent below its 52-week high, after Boxabl secured approval to sell its Casita Studio in Texas. Shareholders are set to vote June 9 on the proposed merger, which would list the combined company as BXBL on Nasdaq if approved.
Casey’s Shares Move Lower Ahead of Results, With Margin Uncertainty in Focus
Casey’s General Stores shares fell 1.9% to $809.41 in early trading Tuesday, even as Wells Fargo raised its price target to $910. The drop came as U.S. indexes climbed, with the S&P 500 up 0.6% and the Nasdaq hitting a record. Wells Fargo warned of a possible fourth-quarter EPS miss due to weaker fuel margins. Casey’s will report fiscal Q4 and full-year results after the bell on June 9.
AeroVironment Stock Jumps As $20 Million Missile-Factory Push Puts Drone Defense Back In Play
AeroVironment shares rose 4.6% to $182.26 after announcing a $20.2 million government investment to expand its Huntsville, Alabama, site for Freedom Eagle-1 interceptor production. The 24,000-square-foot facility will support initial and full-rate manufacturing for U.S. Army needs. The move follows recent Army contracts worth nearly $193 million. Trading volume topped 1.6 million shares amid a strong tech market session.
Zenas BioPharma Stock Slips as a June Catalyst Moves Into View
Zenas BioPharma shares fell 1.3% to $18.73 on Tuesday, underperforming the biotech sector ahead of a June 4 presentation of Phase 3 data for its autoimmune drug obexelimab. The trial showed a 56% reduction in IgG4-RD flare risk, below Amgen’s Uplizna, which cut risk by 87%. Zenas plans to seek FDA approval this quarter. Investors remain cautious as the stock trades well below its 52-week high.
CEPT Stock Sits Quiet, But Cantor Equity Partners II Keeps Some Attention
Cantor Equity Partners II Inc. fell 2 cents to $12.95 Tuesday as traders watched its planned merger with Securitize. About 433,600 shares traded in a $12.75–$13.05 range, putting market cap near $396 million. CEPT’s price stayed above its $10 IPO level, reflecting interest in the Securitize deal. The merger still faces shareholder approval and regulatory hurdles.
New Fortress Energy Shares Dip Under 60 Cents Ahead of Key Reverse-Split Vote
New Fortress Energy Inc. fell to 55.79 cents early Thursday, down 3.8%, with a market value near $159 million after releasing its annual meeting proxy. The company faces possible Nasdaq delisting after months below $1 per share and reported a Q1 net loss of $399.95 million on $226.95 million revenue. Debt stood at $8.29 billion as of March 31, with most classified as current due to defaults. Shareholders will vote June 17 on a 1-for-50 reverse split and restructuring plan.
Diodes Slides; New Auto Chip Launch Puts Focus Back on Growth Track
Diodes Incorporated shares fell 0.7% to $108.36 late Thursday morning after the company launched a new automotive-grade USB-C charging chip. First-quarter revenue rose 22.1% to $405.5 million, with automotive sales up over 32% year-on-year. Diodes forecasts Q2 revenue around $435 million and adjusted EPS of 60 cents. Investors remain focused on margins and order growth amid mixed peer performance.
Axiom Intelligence stock moves after $3.5 billion Terra SPAC deal
Axiom Intelligence Acquisition Corp 1 shares edged up to $10.36 after announcing a merger with Swiss quantum tech firm Terra Quantum, valuing Terra at nearly $3.5 billion. The companies agreed to combine on May 25, with plans to list the merged entity as “TQ” on Nasdaq. Terra Quantum could raise up to $190 million if Axiom shareholders do not redeem shares. The deal awaits shareholder and regulatory approval.
RF Acquisition Corp III Trades Around $10 as SPAC Deals Spotlight RFAM
RF Acquisition Corp III (RFAM) last traded at $9.88, down 2 cents, with 2,967 shares changing hands. The pre-deal SPAC’s trust account held $100.4 million as of March 31. Nineteen SPAC IPOs raised about $2.52 billion in May, according to Boardroom Alpha, but no new SPAC IPOs priced Thursday. RFAM is seeking acquisition targets in Asia, excluding Greater China.
Big Digital Energy Stock Drops as Its AI-Power Pivot Runs Into a Cash Test
Big Digital Energy Inc. shares fell 20 cents to $6.46 in Nasdaq trading Thursday, underperforming larger bitcoin-mining peers. The company reported Q1 revenue dropped to $4.8 million from $13.8 million a year earlier, with operations losing $8.2 million and cash use of $17.1 million. Big Digital ended March with $2.4 million in cash and warned of “substantial doubt” about its ability to continue as a going concern.
Lam Research slips from highs as Wall Street’s AI trade cools
Lam Research shares fell 2.6% to $310.58 Thursday morning on Nasdaq, following a recent rally and a new Mizuho price target of $380. Peers Applied Materials and KLA also declined. Lam reported March-quarter revenue of $5.84 billion and projected June-quarter revenue of $6.6 billion. The company gets 34% of its revenue from China, raising exposure to U.S. export curbs.
Great Elm Capital Stock Moves After Debt Clearance
Nasdaq suspended trading in Great Elm Capital’s 5.875% notes due 2026 on May 28 after the company redeemed all outstanding notes as planned. GECC shares last traded at $6.03, up 3 cents, with a market cap near $84.3 million. Net asset value fell to $7.74 per share in Q1, while the board declared a 25-cent quarterly dividend.
Satellogic stock pops on $18 million injection, 10 million-share filing appears
Satellogic Inc. rose 1.6% to $9.93 Thursday after announcing an $18 million, one-year defense contract and a major shareholder’s plan to sell 10 million shares. The stock traded between $9.47 and $10.11, with market cap near $1.40 billion. First-quarter revenue climbed 80% to $6.1 million, and the company reported positive operating cash flow. Liberty Strategic Capital filed notice to sell shares worth $97.7 million.
FTC Solar Gets Lift as Traders Watch $543 Million Backlog
FTC Solar shares rose 0.6% to $5.43 in early Nasdaq trading Thursday, bucking declines in other solar-tracker stocks and small-cap indexes. First-quarter revenue fell 47.5% from the prior quarter to $17.3 million, with a GAAP gross loss of $1.2 million. The company named Anthony Carroll as CEO in late April. Backlog stood at about $543 million.
Moderna Shares Dip With FDA Vote Putting COVID Vaccine Plan to Test
Moderna shares fell 2.6% to $46.39 Thursday as an FDA advisory panel met to discuss the 2026-2027 COVID-19 vaccine formula, focusing on the XFG strain. The company reported a Q1 net loss of $1.3 billion and $389 million in revenue, mostly outside the U.S. FDA advisers will review Moderna’s mRNA flu shot for older adults on June 18. Wall Street analysts remain divided on the stock’s outlook.
Werner Enterprises Stock Trades Close to 52-Week High on Freight Rebound Hopes
Werner Enterprises traded at $40.92 before Thursday’s open, near its 52-week high, giving the company a market cap of about $2.45 billion. First-quarter revenue rose 14% to $808.6 million, with operating income at $4.0 million after a loss last year. The FirstFleet acquisition added $107.9 million in revenue but increased leverage risks. Werner’s next public appearance is set for June 9 at a Wells Fargo conference.
Radware Drops 3% After Shareholder Vote
Radware shareholders approved all three proposals at the May 25 annual meeting, the company said Wednesday. Shares closed down 3% at $29.00, below the 52-week high. First-quarter revenue rose 11% to $79.8 million, with cloud annual recurring revenue up 23%. Americas revenue climbed 40%, while EMEA fell 11%.
Sportradar shares take a hit after latest analyst move
JPMorgan downgraded Sportradar Group AG to Neutral from Overweight and cut its price target to $16 from $26. Shares closed Wednesday at $12.89 on Nasdaq, down 0.8%, and have fallen about 46% this year. The company faces scrutiny after short-seller claims and a securities lawsuit. First-quarter revenue rose 11% to 347 million euros, but Sportradar posted a 6 million euro loss.
Integrated Media Technology Faces Nasdaq Cutoff, Reverse-Split Vote Ahead
Integrated Media Technology shares traded at $0.5224 in U.S. premarket on May 28, remaining below Nasdaq’s $1 minimum bid requirement. Shareholders will vote June 9 on a reverse split to boost the share price. The company faces a June 29 deadline to regain compliance or risk delisting. Shares are down 55.7% over the past year.
Next Technology Stock: NXTT’s Bitcoin Bet Is Back In Focus Before Thursday’s Open
Next Technology last traded at $1.34 before Thursday’s open, after closing up 3.1% Wednesday. The company held about 5,833 bitcoin at March 31, reporting a $126.5 million fair-value loss on digital assets and a first-quarter net loss of $105.9 million. Cash rose to $159.7 million after a $157 million share sale in March. NXTT had 76.3 million shares outstanding as of April 29.
Xerox jumps as 15 million-share filing gives turnaround hope
C4 Therapeutics shares traded at $3.74 before the Nasdaq open on May 28, holding gains after a 7.16% rise the prior session. The move comes as investors await cemsidomide updates at ASCO and EHA meetings. C4 reported $268.3 million in cash at March 31 and a narrowed Q1 net loss. The company expanded its Roche partnership in April, securing a $20 million upfront payment.
Rail Vision Stock Slides Before the Bell as Tiny AI Rail Bet Faces Fresh Test
Rail Vision Ltd. shares fell 2.1% to $4.65 in thin pre-market trading Thursday, after dropping 4.6% in the prior session. The stock remains near recent lows and has not issued a new company update since May 20, when it announced a quantum AI dataset integration by its Quantum Transportation unit. RVSN closed at $6.07 on May 19 and has traded between $3.66 and $29.57 over the past year.
Imunon Shares Trade Early After CEO Gets Stock Grant
Imunon shares rose 3.5% to $2.38 in thin pre-market trading Thursday after an SEC filing showed CEO Stacy Lindborg received 1,491 shares instead of part of her cash salary. The company has warned of “substantial doubt” about its ability to continue operating. Only 531 shares changed hands pre-market. Imunon’s main drug, IMNN-001, remains in Phase 3 trials for advanced ovarian cancer.
Jade Biosciences Gets Two Catalysts, but Focus Is on 2027
Jade Biosciences began dosing patients in Phase 2 and first-in-human trials for kidney disease and rheumatoid arthritis. Shares traded at $21.50 premarket, down 21 cents. Interim data for both drugs are expected in 2027. Jade reported $311.3 million in cash as of March 31, enough to fund operations into 2028.
June 1 On Deck for Liberty Latin America After Malone Buy, 9% Yield: LILA Watch
Liberty Latin America Class A shares traded at $7.84 premarket, down 16 cents, after John C. Malone bought over 12 million Class C and 61,000 Class A shares from Liberty Capital for $8.63 each, according to an SEC filing. Nasdaq will begin when-issued trading for the company’s new preferred-share payout June 1, with payment set for June 16. First-quarter revenue was $1.083 billion; adjusted free cash flow was negative $64 million.